To investigate the effects of Active Hexose Correlated Compound (AHCC) supplementation and the mechanism action of AHCC in patients with a lcohol-induced mildly elevated liver enzyme levels. participants were randomly a llocated to the placebo. l g AHCC. or 3 g AHCC group and took the supplement for 12 wk. Subjects visited the hospital for clinical and biochemical measurements, for examination of adverse events. to return unused supplements. and to obtain their next supplements. Biochemical tests including liver enzymes. a questionnaire survey. and anthropometric measurements were collected at baseline and every 4 wk thereafter. Adherence and adverse events were eva luated. After 12 wk of supplementation. the percentage change in alanine aminotransferase (ALT) level was significantly different between the placebo (4.02:!: 59.07%) and both AHCC groups (1 g AHCC: -23.89 :!:20.59%, 3 g AHCC: -24.09:!:30.73%) (p= 0.04). Serum levels of tumor necrosis factor-a (p< 0.05) a nd interleukin-1/3 (p< 0.01) were significantly lower. while those of adiponectin were higher in both AHCC groups than in the placebo group (p< O.Ol ). AHCC supplementation for 12 wk may improve the levels of liver enzymes and circulating pro-inflammatory and anti-inflammatory cytokines in patients with alcohol-induced liver enzyme elevation with mildly elevated liver enzyme levels.
Deaths attributable to a lcohol comprise approximately 4% of all deaths worldwide ( I). Alcoholic liver diseases. including fatty liver. hepatitis. cirrhosis. and cancer. account for a quarter of such deaths ( 1 ). Patty liver. which is present in more than 90% of heavy drinkers. is asymptomatic and reversible with a lcohol abstinence. However. with continued alcohol consumption. hepatic inflammation and injury. a condition known as a lcoholic hepatitis. can occur. The prognosis of alcoholic hepatitis is variable, with nearly 100% survival in mild cases as compared to high s hort-term mortality in severe cases (2) . Patients with continued excessive alcohol intake are at risk for the development of fibrosis and cirrhosis. Twenty to forty percent of patients with fatty liver will progress to fibrosis. of which 8-20% will develop cirrhosis (3) . Despite the profound impact of alcoholic Liver disease on public health, there are currently no effective treatments. and. other than abstinence. no preventive measures.
Although alcohol is considered a direct hepatotoxin. its resultant hepatic injury involves complex interaction s with additional fa ctors that remain incompletely defined (4) . Oxidative stress and inflammatory cytokines have been investigated for their roles in the alcohol-induced liver inflammatory response (5. 6) . Several clinical trials examining the effects of antioxidants (7. 8) or tumor necrosis factor (TNF)-a inhibitors (9. 10) have been conducted in alcoholic hepatitis patients: however, evidence for these treatments in alcoholic liver disease is still lacking.
Active Hexose Correlated Compound (AHCC). extracted from several species of Basidiomycetes mushrooms. is a mixture of carbohydrates including oligosaccharides, amino acids. lipids, and minerals derived from fungi ( 11 ) . The active ingredients of AHCC are a -glucan. acetylated a-glucan, and /3-glucan of polysaccharides ( 12) . It has been suggested that AHCC has anti-oxidative ( 1 I ), anti-inflammatory ( 12. 13) and immunostimulatory effects ( 14. 15) as well as hepatoproteclive properties in vitro (16. 1 7) and in vivo ( 12) .
As in other liver diseases. patients with cirrhosis are at risk for ascites, variceal bleeding, and encephalopathy from hepatic decompensation and hepatocellular carcinoma. Despite some advances in our understanding of the natural history. pathogenesis and clinical characteristics of alcoholic liver disease. relatively few advances have been made in the treatment field. Novel therapies are thus needed. In previous research. the effect of AI-ICC on liver disease was studied only in hepatocellular carcinoma patients ( 18) . We intended to investigate the effects of AHCC supplementation and the mecha- 
METHODS
This study was approved by the Institutional Review Board of Chung-Ang University Hospital. Seoul. Republic of Korea (C2009068(255)). and complied with the code of ethics of the World Medical Association (Declaration of Helsinki). Written informed consent was obtained from a ll participants.
Study design and participallls. This study was a randomized. controlled. double-bLind clinical trial conducted between May and September 2010 at the Chung-Ang University Healthcare System in Seoul. Eligible participants with elevated Liver enzyme level associated with alcohol consumption were consecutively recruited. The inclusion a nd exclusion criteria a re shown in detail in Table 1 .
Preparation of AHCC. Capsules for the trial were su pplied by Amino Up Chemical Co .. Ltd. (Sapporo. Japan). Each capsule was a Light brown color and contained 167 mg of AHCC with 333 mg of dextrin a nd malt extract or a placebo of dextrin and malt extract. AHCC is an enzyme-fermented extract of the Basidiomycetes mushroom that is available as a dietary supplement. The complex compound contains a mixture of polysaccharides. amino acids. lipids. and minerals ( 12) . The predominant components are oligosaccharides. totaling approximately 71.2% of the total dry weight (12) .
Interventions. The treatment duration was set at 1 2 wk since the effect of AHCC appeared after 3 mo in a previous study (19) . Patients were treated 30 min before breakfast and dinner for 12 wk with 3 g/d AHCC (500 mg of AHCC/capsuleX3 capsulesX2 doses) for the 3 g AHCC group. 1 g/d of AHCC (167 mg of AHCC with 333 mg of dextrin and malt extract/capsule X3 capsules X2 doses) for the 1 g AHCC group. and caps ules with dextrin and malt extract for the placebo group. Throughout the study. all participants were asked to maintain their regular diet. lifestyle. and routine oral medications, except any medications affecting liver enzymes such as acetaminophen. non-steroidal anti-inflammatory drugs, anti-viral agents. HMG-CoA reductase inhibitors, steroids. and agents for liver disease treatment such as ursodeoxycholic acid, biphenyldimethyl-dicarboxylate, silymarin, Carduus marinanus extract. or herbal supplements.
Outcome assessment. After the screening visit, each participant visited the hospital three times for clinical and biochemical measurements. examination of adverse events. return of unused s upplements. and their next supply of supplements every 4 wk. When the value of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) in the study period increased 2-fold or more compared to the baseline or previous value. s ubjects were dropped from this study. The primary outcomes evaluated were the value and the percentage change of three liver enzymes (AST. ALT. and gamma-glu tamyl transferase {r·-GT)) in each group. The percentage change was calculated using this formula: [(after supplementation-baseline)/baseline] X 100. The secondary outcomes analyzed were the biochemical parameters and questionnaire scores in each group.
Biochemical tests were performed on blood samples 1 Brief encounter psychosocial instrument-K. 2 Homeostasis model assessment of insulin resistance. 3 Blood urea nitrogen. 4 Tumor necrosis factor-a. 5 Interleukin-1/3. Oat<J are shown as mean :!:standard deviation and median (25-75%). p-values were calculated by ANOVA and Kruskai-Wallis test. 1 Brief encounter psychosocial instrument-K. 2 Homeostasis model assessment of insulin resistance. 3 Blood urea nitrogen. 4 Tumor necrosis factor-a. 5 1nterleukin-l {3.
collected after overnight fasting {> 12 h). White blood cells and hemoglobin levels were determined within 1 h after blood collection using the ADVTA 120 automated hematology analyzer {Siemens, Tarrytown. NY). Serum levels of AST, ALT. y-GT. bilirubin. albumin, blood urea nitrogen. creatinine. fasting glucose. total cholesterol. HDL-cholesterol. and triglycerides were measured using an ADVfA 1650 Chemistry system {Siemens). LDL-cholesterol was calculated using Friedewald's formula [LOL-cholesterol = total cholesterol-HDLcholesterol-(triglyceride/ 5)] if the serum triglyceride level was below 400 mg/ dL. Fasting insulin levels were measured by electrochemiluminescence immunoassay (Roche. Indianapolis. IN). and insulin resistance was estimated using the homeostasis model assessment of insulin resistance (HOMA-IR) index [(insulin (FLlU/ mL)Xfasling blood glucose (mg/dL)/ 18)/22.5]. Interleukin {IL)-l/3 and TNF-a levels were measured using a commercially-available enzyme-linked immunosorbent assay (R&D. Minneapolis. MN). The intra-and inter-assay coefficients of variation were 5.3±2.8% and 8.4 ± 1.9% forTNF-a. a nd 6.7±3.}0;' ., and 5.6 ± 4.5% for IL-1{3. Plasma adiponectin levels. a n anti-inflammatory ad ipokine. were measured using an enzyme immunoassay kit (AdipoGen. Seoul. Korea) with inter-and intraassay variability of 4.63%±0.82% and 2.72%±0.52%. respectively.
Fatigue and mental stress was measured via questionnaire. The brief fatigue inventory (BPI) composed of simple numeric rating scales from 0 to 10 was used for assessing fatigue. Severe fatigue was defined as a worst fatigue score of 7 or greater. For mental stress assessment. the Korean brief encounter psychosocial instrument {BEPSI-K). a validated indicator of perceived stress. was used. BEPSI-K consists of 5 items on a 1-5 Likert scale.
Anthropometric measurements were performed in the morning after overnight fasting while subjects were wearing light clothing and no shoes by a single observer. A body composition analyzer (Inbody 3.0, Biospace, Seoul. Korea) was used to measure their heights a nd body weights. The body mass index (BMI) was calculated by dividing the measured weight (kg) by the squa re of height (m 2 ) . Subjects sal on a chair in a stable and relaxed state. and their blood pressure was measured using a mercurial blood pressure tonometer. KIM H el a l. Adherence was expressed as a percentage. calculated by taking the number of supplements ingested divided by the number the patient should have ingested and multiplying by 100. The number of supplements ingested was examined as the number of capsules given minus the number of capsules returned at the next visit. The incidence and type of adverse events were also included in the outcome parameters.
Randomization and concealment. The random allocation sequence was generated by a sponsor through SAS implementation with PROC PLAN. Subjects were included in one of three groups with equal probability. The sponsor provided a research pharmacist with supplements numbered according to the random allocation sequence. A clinical investigator received 69 sealed envelopes containing a sheet noting the assigned group from the sponsor. The investigator opened the relevant envelope only when an adverse event occurred a nd then announced the assigned group to the participant.
Blimling. Both study participants and all investigators. including a research nurse who contacted the participants. a research pharmacist. and a physician. were blinded after assignment to interventions.
Smnple size. The estimated minimum number of required patients according to an anticipated difference in ALT value of 15 with a standard deviation of 13. a two-tailed a=0.05. and a {3=0.2 was 48 subjects (16 patients per each group). Taking into account an estimated 30% dropout rate. we enrolled total 69 participants.
Statistical analyses. Even after logarithmic transformation. variables such as IL-1{3. TNF-a. fasting insulin and HOMA-IR did not have a normal distribution; Significance was defined at the 0.05 level. The data was processed with an SAS 9. 1 statistics package (SAS lnslitute rnc. Cary. NC). All values with normal distribution are expressed as the mean ± SD. and the others as the median (25-75%).
RESULTS
Among 78 screened patients who were suspected of having alcoholic liver disease. 69 patients were eligible and were randomly assigned to one of the three groups. Demographic. clinical. and biochemical characteristics are given in Table 2 . During the study. seven patients dropped out. Of those who dropped out. four patients discontinued due to disinclination (1 g AHCC group: n= 2. 3 g AHCC group: n= 1. placebo group: n= 1). and in the placebo group. three participants experienced mild gastrointestinal distress. There were no adverse events in either AHCC group. A total of 62 participants completed the study (Fig. 1 ) . Adherence of the study participants was 92.4:t6.8% with n o significant difference between the groups (p=0.88). The mean clinical and biochemical outcomes at 12 wk were analyzed with ANOVA ( Table 3 ). The liver enzyme levels, lipid profiles, insulin resistance. and scores on fatigue a nd stress-related questionnaires did not show significant differences between the groups (p> 0.05): however. cytokine levels did show significant differences (TNF-a. IL-1,8 and adiponectin. p< 0 .05).
Comparing the percentage ch anges at 12 wk as analyzed by a paired t-test. a decrease in liver enzymes in both AHCC groups (Fig. 2) and a change in lL-1,(3 and adiponectin in the 1 g AHCC group (Fig. 3 ) were found to be statistically significant. When analyzed with ANOVA. the percentage changes of serum levels of inflammatory cytokines. such asTNF-a (p< O.OS) and IL-1,(3 (p< 0.01). were lower in the AHCC supplementation groups th an th e pl acebo group (Fig. 3) . Serum levels of adiponectin were higher in both AHCC groups than in the placebo group (p< 0.05, Fig. 3) . Figure 4 depicts the percentage ch an ges in three hepatic enzymes analyzed with ANOVA. The comparison of mean percentage changes was not found to be significantly different among the three groups except for ALT after 12-wk supplementation.
The association between changes in hepatic enzymes (AST. ALT. and -y-GT) and changes in cytokines (TNFa, IL-1,(3. a nd adiponectin) was analyzed ( Fig. 5 ). There were positive relationships a mong percentage ch anges in hepatic enzymes. The percentage change of IL-1,8 was positively correlated with that of ALT (7=0.25. p= 0.02). whereas an inverse relationship was revealed between adipon ectin and IL-1,8 (7= -0.40. p< O.Ol). and adipon ectin and TNF-a (7=-0.36, p< O.Ol). Though not significant. a tendency toward a positive correlation of the percen tage change between TNF-a and y-GT (7=0. 19 , p= 0.07) and an inverse cor relation between adiponectin and AST (r = -0.26. p = 0 .09) was observed.
DISCUSSION
In this double-blind. randomized controlled trial. we examined whether AHCC is effective in liver injury caused by chronic and excessive alcohol ingestion and whether the effects of AHCC are dose-dependent. AHCC su pplementation for 12 wk significa ntly improved ALT levels. decreased pro-inflammatory cytokines (TNF-a a nd IL-1,(3), and elevated anti-inflammatory cytokines (adiponectin) in both AHCC groups a fter 1 2 wk of supplementation without any adverse events. Hepatoprotectivc effects accompanied by striking anti-inflammatory effects were observed regardless of the dosage.
Ingestion of alcohol initiates a variety of metabolic responses that influence the final hepatotoxic response (4) . Pro-inflamma tory cytokines including TNP-a, IL-1,(3. and interferon-y, are regarded as m ajor contributors to the development of alcohol liver injury (5. 6) . In contrast. adiponectin , a fa t-derived anti-inflammatory adipokine. is considered to play a protective role in fatty liver suppression by upregulation of AMP-activated protein kinase (AMPK). peroxisome proliferator-activated receptor (PPAR)-a, and PPARy coactivator (PGC)-1a. and reduction of lipopolysaccharide (LPS)-stimulated TNF-a production and the TNF-a mediated inflammatory response in alcoholic liver disease (5) . Increased expression of iNOS is known to be associated with alcohol-induced hepatic dysfunction (20. 2 1 ) . Pro-in[)ammatory cytokines also induce expression of the iNOS gene (22. 23) . In iNOS-knockout mice. a lcohol-induced liver injury with elevated serum AL'f levels and fatty liver was prevented (24) . The iNOS inhibitor. N-(3-aminomethyl) benzylacetamindlne. showed similar protec-(I) (4) (7) . . . .. :· . :: ;· . . .. . tive effects in alcohol-induced liver dama ge (24) . Endotoxins have been accepted as another pathophysiologic mechanism of alcoholic liver disease ( 4) . Chronic a lcohol ingestion promotes hepatic inflammation by increasing translocation of gut-derived endotoxins to the portal circulation and activating Kupper cells through the LPS/ Toll-like receptor (TLR)-4 (5) .
AHCC has been utilized for over a decade in Japan, and the typical daily recommended dose of AHCC-fine granules (60% AHCC-freeze dried preparation) is 3 gin clinical practice (25) . The safety of AHCC as a dietary supplement has been reported in several studies evaluating genotoxicity o r acute and subchronic oral toxicity ( 14, 25, 26) .
In previous research, AHCC was shown to improve liver enzymes through t h e modulation of pro-and anti-inflammatory cytokines (12, 13 ) . In rats with hapten-induced colitis. AHCC administration reduced pro-inflammatory cytokines, including TNF and IL-1/3. as well a s colonic inflammation (13) . AHCC increased detoxification enzymes in t he liver and protected the liver from CCI4-(2 7) and ferric nitrilotriactate (Fe-NTA)induced injury (28) . AHCC administration normalized elevated liver enzyme levels in 6-mercaptopurine and m ethotrexate-induced liver injury in mice (I 2). In humans, AHCC intake improved the levels of AST a nd y-GT in postoperative hepatocellular carcinoma patients ( .18). In accordance with previous research. our study showed improvem ent of the levels of liver enzymes and circulating pro-inflammatory and anti-inflammatory cytokines in patients with mildly e levated liver enzyme levels.
AHCC suppressed iNOS gene expression through inhibition of the Akt/type I IL-l receptor (IL-lRI)dependent pathway in hepatocytes ( 1 7). AHCC can decrease hepatic inflammation by reducing gut-derived endotoxins in alcoholic liver disease and increasing aerobes, lactic acid bacteria, and bifidobacteria in addition to decreasing clostridium in the feces of colitis rats through its role as a prebiotic (13) . The colonic microflora of hapten-induced colitis rats treated with AHCC was different from that of not only non-treated hapteninduced colitis rats but also normal controls (1 3). Oligosaccharides. a main component including the a ctive ingredient. may accelerate the growth of normal flora in the gut. inhibit the growth of pathogenic microorganisms (29. 30) . and prevent bacterial translocation through their interaction with bacteria (31, 32) .
The current study has limitations. First, the number of study participants was small and the study period was relatively short. In order to elucidate the beneficial action m echanism of AHCC for alcoholic liver disease patients. studies that include measurements of serum endotoxin levels and the identification of intestina l flora through fecal culture are necessary.
CONCLUSION
Our results demonstrated promising effects with a 12-wk course of AHCC supplementation for improving liver enzyme levels and circulating pro-inflammatory and a nti-inflamma tory cytokines in patients with alcohol-induced liver enzyme elevation.
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